Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.22.9587

Olanzapine for Preventing Nausea and Vomiting Induced by Moderately and Highly Emetogenic Chemotherapy  

Wang, Shi-Yong (Department of Biotherapy and Laboratory of Biotherapy, the Fourth Affiliated Hospital of China Medical University)
Yang, Zhen-Jun (Department of Medical Information, Shengjing Hospital of China Medical University)
Zhang, Lu (Department of Biotherapy and Laboratory of Biotherapy, the Fourth Affiliated Hospital of China Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.22, 2014 , pp. 9587-9592 More about this Journal
Abstract
Nausea and vomiting are common adverse events in chemotherapy. In spite of the serious effects on the quality of life and further treatment, they remain overlooked by physicians, and no standard treatment has been developed. Neurokinin-1 (NK-1) receptor antagonists and palonosetron are the major agents in the standard regimen for treating moderately and highly emetogenic chemotherapy-induced nausea and vomiting (CINV). However, NK-1 receptor antagonists first became commercially available at the end of 2013 and palonosetron has not been extensively applied in China. Olanzapine was recommended as a therapy for moderate and severe CINV in antiemesis-clinical practice guidelines in oncology in 2014 for the first time. It is an atypical antipsychotic agent, which can block multiple receptors on neurotransmitters. During more than 10 years, olanzapine has demonstrated significant effects in preventing CINV and treating breakthrough and refractor CINV, which was observed in case reports, precise retrospective studies, and phase I, II and III clinical trials, with no grade 3 to 4 adverse events. In particular, it is superior to aprepitant and dexamethasone in delayed nausea and vomiting. Therefore, this compound is worthy of further investigation.
Keywords
Olanzapine; chemotherapy-induced nausea and vomiting; malignant neoplasm; clinical trials;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Ito F, Chang AE (2013). Cancer immunotherapy: current status and future directions. Surg Oncol Clin N Am, 22, 765-83.   DOI
2 Janelsins MC, Tejani MA, Kamen C, et al (2013). Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother, 14, 757-66.   DOI
3 Keat CH, Ghani NA (2013). Cost-effectiveness analysis of granisetron-based versus standard antiemetic regimens in low-emetogenic chemotherapy: a hospital-based perspective from Malaysia. Asian Pac J Cancer Prev, 14, 7701-6.   과학기술학회마을   DOI   ScienceOn
4 Li F, Zhao C, Wang L (2014). Molecular-targeted agents combination therapy for cancer: developments and potentials. Int J Cancer, 134, 1257-69.   DOI
5 McIntyre RS, Cha DS, Kim RD, et al (2013). A review of FDAapproved treatment options in bipolar depression. CNS Spectr, 18, 4-20.
6 Mizukami N, Yamauchi M, Koike K, et al (2013). Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manage, [Epub ahead of print].
7 Moore MA, Sangrajrang S, Bray F (2014). Asian cancer registry forum 2014 - regional cooperation for cancer registration: priorities and challenges. Asian Pac J Cancer Prev, 15, 1891-4.   과학기술학회마을   DOI
8 Navari RM, Einhorn LH, Passik SD, et al (2005). A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer, 13, 529-34.   DOI   ScienceOn
9 Navari RM, Einhorn LH, Loehrer PJ Sr, et al (2007). A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer, 15, 1285-91.   DOI
10 Navari RM, Gray SE, Kerr AC (2011). Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol, 9, 188-95.   DOI
11 Navari RM, Nagy CK, Gray SE (2013). The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer, 21, 1655-63.   DOI
12 Navari RM (2014). Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol, 722, 180-6.   DOI
13 NCCN clinical Practice guidelines in oncology- Antiemesis Version I, 2014. http://www.nccn.org/professionals/ physician_gls/f_guidelines.asp#supportive.
14 Pirl WF, Roth AJ (2000). Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncol, 9, 84-7.   DOI
15 Passik SD, Lundberg J, Kirsh KL, et al (2002). A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage, 23, 526-32.   DOI
16 Passik SD, Kirsh KL, Theobald DE, et al (2003). A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage, 25, 485-8.   DOI
17 Daher M (2012). Cultural beliefs and values in cancer patients. Ann Oncol, 23, 66-9.   DOI
18 Brafford MV, Glode A (2014). Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol, 5, 24-9.
19 Copier J, Bodman-Smith M, Dalgleish A (2011). Current status and future applications of cellular therapies for cancer. Immunotherapy, 3, 507-16.   DOI
20 Chen W, Zheng R, Zhang S, et al (2014). Annual report on status of cancer in China, 2010. Chin J Cancer Res, 26, 48-58.
21 Flank J, Sung L, Dvorak CC, Spettigue W, Dupuis LL (2014). The Safety of Olanzapine in Young Children: A Systematic Review and Meta-Analysis. Drug Saf . [Epub ahead of print]
22 Hesketh PJ, Grunberg SM, Gralla RJ, et al (2003). The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol, 21, 4112-9.   DOI   ScienceOn
23 Hassan BA, Yusoff ZB (2010). Negative impact of chemotherapy on breast cancer patients QOL - utility of antiemetic treatment guidelines and the role of race. Asian Pac J Cancer Prev, 11, 1523-7.
24 Hocking CM, Kichenadasse G. (2014). Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer, 22, 1143-51.   DOI
25 Sliwkowski MX, Mellman I (2013). Antibody therapeutics in cancer. Science, 341, 1192-8.   DOI
26 Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al (2003). Cancer. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer, 97, 3090-8.   DOI   ScienceOn
27 Passik SD, Navari RM, Jung SH, et al (2004). A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest, 22, 383-8.   DOI
28 Roila F, Herrstedt J, Aapro M, et al (2010). Guideline update for MASCC and ESMO in the prevention of chemotherapyand radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol, 21, 232-43.   DOI
29 Siegel R, Ma J, Zou Z, et al (2014). Cancer statistics, 2014. CA Cancer J Clin, 64, 9-29.   DOI
30 Tan L, Liu J, Liu X, et al (2009). Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res, 28, 131.   DOI
31 Uchino J, Hirano R, Tashiro N, et al (2012). Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy. Asian Pac J Cancer Prev, 13, 4187-90.   과학기술학회마을   DOI
32 Vardy J, Chiew KS, Galica J, et al (2006). Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer, 94, 1011-5.   DOI
33 Wang XF, Feng Y, Chen Y, Gao BL, Han BH (2014). A metaanalysis of olanzapine for the prevention of chemotherapyinduced nausea and vomiting. Sci Rep, 4, 4813.
34 Vig S, Seibert L, Green MR (2014). Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity. J Cancer Res Clin Oncol, 140, 77-82.   DOI
35 Welti J, Loges S, Dimmeler S, et al (2013). Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest, 123, 3190-200.   DOI
36 Wang SY, He Y, Zhang L, et al (2014). The effects of olanzapine, tropisetron and dexamethasone to preventing the nausea and vomiting induced by multi-day highly or moderately emetogenic chemotherapy in cancer patients. Chinese clinical oncology, CSCO, 544-5.
37 Yuan Lingyan, Jiao Xiaodong, Wang Zhan, et al (2013). Olanzapine combined granisetron and dexamethasone for the prevention of chemotherapy-induced emesis and nausea in cancer patients: A phase I trial. Chinese Clin Oncol, 18, 511-4.